Research programme: glycoprotein therapeutics - Boston TherapeuticsAlternative Names: Ipoxyn
Latest Information Update: 30 May 2014
At a glance
- Originator Boston Therapeutics
- Class Glycoproteins
- Mechanism of Action Oxygen carriers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anaemia; Cardiovascular disorders; Peripheral ischaemia